Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026)

Cellectis' (CLLS) quarterly Total Non-Current Liabilities came in at $94.8 million in Q1 2026, up 11.08% year-on-year from $85.3 million in Q1 2025, and down 8.05% quarter-over-quarter from $103.1 million in Q4 2025.

Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends

Cellectis' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $94.8 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 11.08% year-over-year to $94.8 million in Q1 2026; TTM through Mar 2026 was $94.8 million, a 11.08% increase from a year earlier, with the FY2025 full-year figure at $103.1 million, up 19.51% from the prior year.
  • Total Non-Current Liabilities retreated to $94.8 million in Q1 2026 per CLLS's latest filing, from $103.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $105.4 million in Q1 2024 and bottomed at $70.4 million in Q1 2023.
  • The 5-year median for Total Non-Current Liabilities is $89.6 million (2023), against an average of $90.1 million.
  • Biggest YoY gain for Total Non-Current Liabilities was 10184.24% in 2022; the steepest drop was 24.91% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $72.3 million in 2022, then soared by 30.65% to $94.4 million in 2023, then dropped by 8.67% to $86.2 million in 2024, then increased by 19.51% to $103.1 million in 2025, then fell by 8.05% to $94.8 million in 2026.
  • Per Business Quant, the three latest CLLS Total Non-Current Liabilities figures stand at $94.8 million (Q1 2026), $103.1 million (Q4 2025), and $94.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Cellectis 281.48 Mn 95.81 Mn - 94.77 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 94.77 Mn
Dec 31, 2025 103.07 Mn
Sep 30, 2025 93.99 Mn
Jun 30, 2025 89.42 Mn
Mar 31, 2025 85.31 Mn
Dec 31, 2024 86.24 Mn
Sep 30, 2024 100.80 Mn
Jun 30, 2024 98.90 Mn
Mar 31, 2024 105.45 Mn
Dec 31, 2023 94.43 Mn
Sep 30, 2023 89.63 Mn
Jun 30, 2023 89.07 Mn
Mar 31, 2023 70.45 Mn
Dec 31, 2022 72.28 Mn
Sep 30, 2022 80.94 Mn
Jun 30, 2022 85.08 Mn
Mar 31, 2022 91.80 Mn
Dec 31, 2021 96.25 Mn
Sep 30, 2021 787,000.00
Jun 30, 2021 103.80 Mn